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MaBACKGROUND Electrophysiological, imaging, and pathological studies have reported the presence of subtle structural
abnormalities in hearts from patients with Brugada syndrome (BrS). However, data concerning disease involvement
outside of the right ventricular outflow tract are limited.
OBJECTIVES This study sought to characterize the presence and distribution of ventricular myocardial fibrosis in a
cohort of decedents experiencing sudden cardiac death caused by BrS.
METHODS The authors evaluated 28 whole hearts from consecutive sudden cardiac death cases attributed to BrS and
29 hearts from a comparator group comprised of noncardiac deaths (control subjects). Cardiac tissue from 6 regions
across the right and left ventricle were stained with Picrosirius red for collagen and tissue composition was determined
using image analysis software. Postmortem genetic testing was performed in cases with DNA retained for analysis.
RESULTS Of 28 BrS decedents (75% men; median age of death 25 years), death occurred in sleep or at rest in 24 of 28
(86%). The highest proportion of collagen was observed in the epicardial right ventricular outflow tract of the BrS group
(23.7%; 95% CI: 20.8%-26.9%). Ventricular myocardium from BrS decedents demonstrated a higher proportion of
collagen compared with control subjects (ratio 1.45; 95% CI: 1.22-1.71; P < 0.001), with no significant interactions with
respect to sampling location or tissue layer. There was insufficient evidence to support differences in collagen proportion
in SCN5A-positive cases (n ¼ 5) when compared with control subjects (ratio 1.23; 95% CI: 0.75-1.43; P ¼ 0.27).
CONCLUSIONS Brugada syndrome is associated with increased collagen content throughout right and left ventricular
myocardium, irrespective of sampling location or myocardial layer. (J Am Coll Cardiol 2021;78:1511–1521) © 2021 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).B rugada syndrome (BrS) is an inheritedarrhythmic disorder diagnosed in the pres-ence of a characteristic type 1 ECG pattern
employing consensus-based criteria (1,2). Since theN 0735-1097
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ABBR EV I A T I ON S
AND ACRONYMS
ACMG = American College of
Genetics and Genomics
BrS = Brugada syndrome
CMR = cardiac magnetic
resonance imaging
CRY-CCP = Cardiac Risk in the
Young Centre for Cardiac
Pathology
IVS = interventricular septum
LV = left ventricular
RV = right ventricular
RVOT = right ventricular
outflow tract
SADS = sudden arrhythmic
death syndrome
SCD = sudden cardiac death
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1512BrS, including those harboring pathogenic
SCN5A variants. Histological findings of
interstitial fibrosis, inflammatory infiltrates,
and fibrofatty infiltration have been
described, suggesting pathological overlap
with cardiomyopathic and inflammatory dis-
orders including arrhythmogenic cardiomy-
opathy and myocarditis (5-7). The presence
of structural abnormalities in BrS are corrob-
orated by abnormal electrical activation and
low voltage areas during electrophysiological
study, where fractionated electrocardio-
grams and conduction delay appear localized
to right ventricular (RV) epicardium (8,9).SEE PAGE 1522Although usually considered a disease
exclusive to the RV, histopathological eval-uation of a small series of autopsied sudden cardiac
death (SCD) decedents with familial evidence for BrS
had suggested increased collagen content within left
ventricular (LV) as well as RV myocardium (10). Some
patients with BrS also exhibit LV midwall late gado-
linium enhancement on cardiac magnetic resonance
imaging (CMR) (11). However, whether BrS results in
pathological abnormalities outside of the RV has yet
to be fully elucidated. In this study, we sought to
characterize the pathological characteristics of the
largest reported cohort of BrS decedents and SCD
cases with familial BrS to date, testing the hypothesis
that BrS is associated with fibrosis within both right
and LV myocardium. Using automated digital pa-
thology software, we performed blinded quantifica-
tion of histological cardiac tissue composition and
collagen content in a clinically validated BrS SCD
cohort in comparison to noncardiac death control
subjects.
METHODS
BACKGROUND. In the United Kingdom, all unex-
pected sudden deaths are referred to the coroner and
an autopsy is performed. The Cardiac Risk in the
Young Centre for Cardiac Pathology (CRY-CCP) at St
George’s, University of London, provides an expert
national cardiac pathology service. Referral to the
CRY-CCP is initiated voluntarily by the coroner’s
pathologist following an unexplained sudden death,
or if there is suspicion of an inherited heart condition.
The center receives whole hearts or cardiac tissue
blocks from >500 referrals of sudden death each year.
Demographics, clinical data, and toxicological and
pathological findings are entered prospectively into a
database. Ethical approval for this study was grantedby the London Stanmore National Health Service
Research Ethics Committee (reference: 10/H0724/38).
STUDY SETTING AND COHORTS. Between 1994 and
2018, 5,205 cases were referred to the CRY-CCP for
specialist cardiac autopsy. A total of 935 cases had
retained cardiac tissue suitable for histopathological
evaluation. Six cases with an antemortem diagnosis
of BrS and 18 sudden arrhythmic death syndrome
(SADS) cases with a familial diagnosis of BrS were
identified over this time period. Of these, 14 cases
(58%) had retained genomic tissue suitable for post-
mortem genetic testing. In addition, cardiac tissue
from 4 SADS cases harboring pathogenic SCN5A var-
iants (with expected loss-of-function) were identified
from the same base SCD cohort (Table 1). The
comparator group (n ¼ 29), referred to as control
subjects, comprised of consecutive noncardiac deaths
referred to the CRY-CCP, where cardiac tissue was
retained following coronial judgment or
inquest (Figure 1).
CARDIAC EXAMINATION. Whole hearts from BrS
and control groups were macroscopically and
microscopically normal following examination by
expert cardiac pathologists. Histological evaluation
was performed at the time of referral with hema-
toxylin and eosin staining. Heart weight, ventricular
chamber diameter, and wall thickness were pro-
spectively recorded. Tissue sections (5-mm thick-
ness) were sampled at the midventricular level or
from the anterior aspect of the right ventricular
outflow tract (RVOT). In total, 6 cardiac regions from
retained tissue sections were evaluated: RVOT; RV;
anterior interventricular septum (IVS); posterior IVS;
anterior LV; and posterior LV. The RV section
included 3 sampled locations from the right ante-
rior, lateral, and posterior walls. Sections were
stained with Picrosirius red for collagen, and slides
were scanned using 20 magnification on an auto-
mated high-resolution scanner (Nanozoomer,
Hamamatsu Photonics).
CLINICAL DATA COLLECTION. Clinical records from
antemortem BrS cases (n ¼ 6) and where SADS fam-
ilies had undergone evaluation at St George’s Hospi-
tal London were retrospectively reviewed before
study inclusion. Inclusion criteria for SADS cases
were as follows: a witnessed sudden death within 1
hour of symptoms, or last seen alive within 12 hours
of death; aged 1-64 years; no prior recorded cardiac
disease; no history of epilepsy; a normal full coroner’s
post mortem; negative toxicology; and a normal
expert cardiac pathologists’ examination (12). In total,
families of 61 SADS probands with retained cardiac
tissue underwent clinical evaluation at St George’s






















BrSA1 BrS F White 60 Died at rest 1 0 1 0 7 (proband) NA Negative
BrSA2 BrS M White 25 Died in sleep 1 0 0 0 6.5 (proband) NA Negative




BrSA4 BrS M White 25 Died in sleep 1 0 0 0 6.5 (proband) NA Negative
BrSA5 BrS M Asian 45 Died at rest 1 0 0 0 6.5 (proband) NA VUS missense
c.50C>T (p.T17I)
BrSA6 BrS M White 37 Died at rest 0 1 1 0 6 (proband) NA Not performed
BrSF7 None M White 31 Died at rest 0 0 0 0 2.5 (mother) 2 Negative
BrSF8 None F White 17 Died in sleep 0 0 0 0 3 (mother) 3 Not performed
BrSF9 None F White 24 Died in sleep 0 0 0 1 3 (mother) 1 Negative
BrSF10 None M White 50 Died immediately
after exertion
0 0 0 0 2 (daughter) 3 Negative
BrSF11 None F White 25 Died in sleep 0 0 0 0 3 (father) 4 Negative
BrSF12 None M White 27 Died at rest 0 0 0 0 2 (mother and father
positive ajmalines)
3 Not performed
BrSF13 None M White 15 Died in sleep 0 0 0 0 2.5 (father and brother
positive ajmalines)
3 Not performed
BrSF14 None M White 23 Died immediately
after exertion
0 0 0 0 4 (mother and sister
positive ajmalines)
3 Not performed
BrSF15 None M White 27 Died in sleep 0 0 0 0 3 (mother and brother
positive ajmalines)
3 Negative
BrSF16 None M White 56 Died in sleep 0 0 0 0 2 (son) 5 Negative
BrSF17 None M White 19 Died in sleep 0 0 0 0 3 (father) 5 Negative
BrSF18 None M White 40 Died at rest 0 0 0 0 2 (sister) 4 Negative
BrSF19 None M White 17 Died in sleep 0 0 0 0 3 (father) 3 Not performed
BrSF20 None M White 24 Died in sleep 0 0 0 0 3 (father) 3 Not performed
BrSF21 None M White 37 Died in sleep 0 0 0 0 3 (father) 3 Not performed
BrSF22 None M White 25 Died during
exertion
0 0 0 0 3 (father) 3 Negative
BrSF23 None M White 23 Died in sleep 0 0 0 0 3 (father) 4 Not performed
BrSF24 None M White 23 Died during
exertion
0 0 0 0 2 (father) 2 Not performed

















BrS ¼ Brugada syndrome; BrSA ¼ Brugada syndrome antemortem; BrSF ¼ Brugada syndrome familial; BrSG¼ SADS cases harboring pathogenic/likely pathogenic SCN5A variants; Dx ¼ diagnosis; FH ¼ family
history; NA ¼ not available; P/LP/VUS ¼ pathogenic/likely pathogenic/variant of uncertain significance; SCD ¼ sudden cardiac death.
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1513Hospital. This included assessment with 12-lead,
signal-averaged, and exercise ECGs; echocardiogra-
phy; and ambulatory cardiac monitoring. Among
families without diagnostic features of an inherited
cardiac condition, an ajmaline provocation challengewas performed according to an established protocol
(13). Cases with a diagnosis of familial BrS were
included in the presence of a spontaneous or drug-
induced type 1 Brugada ECG pattern in the standard
or high precordial leads in at least 1 first-degree














Tissue n = 206
SCN5A Mutations
n = 4
Digital Quantification of Collagen and Fat (RVOT; RV; IVS; Anterior LV; Posterior LV)
Opioid Toxicity n = 22
Noncardiac Trauma n = 3





Flow chart depicting the total number of SCD referrals to the CRY-CCP and selection of BrS cases and noncardiac control subjects with retained cardiac
tissue. BrS ¼ Brugada syndrome; CRY-CCP ¼ Cardiac Risk in the Young Centre for Cardiac Pathology; IVS ¼ interventricular septum; LV ¼ left ventricle;
RV ¼ right ventricle; RVOT ¼ right ventricular outflow tract; SADS ¼ sudden arrhythmic death syndrome; SCD ¼ sudden cardiac death; SGH ¼ St George’s
Hospital London.
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1514relative. Antemortem BrS and familial BrS were
diagnosed based on expert consensus criteria (2).
Electrocardiogram criteria for a type 1 Brugada ECG
pattern consisted of ST-segment elevation with coved
morphology $2 mm in $1 lead among the right pre-
cordial leads.
Demographics and clinical data for SCD and control
cohorts was obtained following review of the CRY-
CCP database. The consensus-derived Shanghai
score was calculated for each decedent with an
antemortem diagnosis of BrS, and for familial BrS
cases, the relative with the highest score following a
diagnosis of BrS (1). SADS cases without familial
evaluation data but with pathogenic or likely patho-
genic SCN5A loss of function variants (as per Amer-
ican College of Medical Genetics and Genomics
[ACMG] criteria [14]) were identified from the same
base cohort. Noncardiac deaths were determined by
information from the referring pathologist’s autopsy
and final coronial judgment.POSTMORTEM GENETIC TESTING. Following extrac-
tion of DNA from retained splenic tissue, cardiac gene
panel testing was performed using the Illumina Tru-
Sight Cardio (174 genes) panel (or a custom Agilent
SureSelect with equivalent content). Libraries were
prepared according to the manufacturer’s in-
structions and sequenced on the Illumina platform
(NextSeq or HiSeq), as previously described and
validated (15,16). In total, 77 inherited arrhythmia-
and cardiomyopathy-related genes were analyzed
across both capture systems (Supplemental Table 1).
Variant annotation was then undertaken in-house
using SnpEff version 4.3T (build 2017-11-24) (17),
GRCh37.75 (Ensembl), and ANNOVAR (version 2017-
07-17) (18). Rare variants were defined as those with
a minor allele frequency cut-off <0.01% in the ExAC
general population database. Nontruncating variants
in TTN and synonymous variants not located at splice
sites were excluded because of their high frequency
and lack of certainty of disease causation. Rare
FIGURE 2 Histological Slide of an RVOT Section From a BrS Decedent
(A) Automated detection of a digitally transformed histological slide from a RVOT section stained with Picrosirius red to determine epicardial
and endocardial layers. (B) Digital characterization of epicardial layer tissue composition using Visiopharm software. (C) Classification of fat
(yellow), collagen (red), and myocytes (orange). Abbreviations as in Figure 1.
J A C C V O L . 7 8 , N O . 1 5 , 2 0 2 1 Miles et al
O C T O B E R 1 2 , 2 0 2 1 : 1 5 1 1 – 1 5 2 1 Biventricular Myocardial Fibrosis in Brugada Syndrome
1515variants were then assessed for pathogenicity ac-
cording to the ACMG criteria (14).
AUTOMATED IMAGE ANALYSIS. Automated calcula-
tion of cross-sectional tissue area and quantification
of collagen (%), myocytes (%), and fat (%) was per-
formed blinded to case or control group using an
application developed within Visiopharm image
analysis software (Visiopharm A/S) (Figure 2), as
previously reported (19). Proportions were calculated
by assessment of collagen and fat area with respect to
automated detection of total tissue area. Perivascular
collagen surrounding epicardial and intramural ves-
sels was excluded because of high variability in vessel
caliber between samples. Exclusion was based on
automated lumen detection (elliptical score $0.4)
incorporating surrounding region of Picrosirius red
stain. Total tissue area was categorized into epicardial
and endocardial regions (50:50). RV (right anterior,
lateral, and posterior sections) and septal (anterior
and posterior IVS) tissue areas were combined for the
purpose of morphometric quantification.
STATISTICAL ANALYSIS. Continuous normal data
are summarized as mean  SD and skewed data are
presented as median (interquartile range [IQR]).Categorical data are presented as groups’ percent-
ages. Differences between group demographics and
macroscopic cardiac appearances were compared us-
ing a 2-sample independent Student’s t-test, Mann-
Whitney U test, or chi-square (Fisher exact) test,
according to their statistical nature and appropriate-
ness of their distributional assumptions. Differences
between groups were assessed through regression
techniques on outcomes defined by proportions
(log transformed) of each tissue component
(% collagen, fat, myocytes). These outcomes gener-
ated hierarchically dependent data per sampling
location (RVOT, RV, IVS, anterior LV, posterior LV)
and tissue area (whole block, endocardial layer,
epicardial layer), incorporating 2 difference sources
of variability. Hence, outcomes were analyzed using
multilevel regression techniques for correct in-
ferences. Potential explanatory variables of age at
death, sex, and body mass index were included in
multivariable analyses. Predictions of collagen and
fat proportion at the original scale were expressed in
terms of geometric means across groups in the data.
Given the exploratory nature of this study, P values
and 95% CIs presented in this report have not been
adjusted for multiple testing. Further investigations
TABLE 2 Comparison of Demographics and Macroscopic Cardiac Appearances Between
BrS Decedents and Control Subjects
BrS (n ¼ 28) Controls (n ¼ 29) P Value
Age at death, y 30.7  12.1 (25) 32.1  9.9 (33) 0.56
Male 21 (75) 25 (86) 0.28
White 26 (93) 28 (97) 0.53
Weight, kg 80.4  13.1 (80) 88.3  21.2 (83) 0.16
Body mass index, kg/m2 26.0  4.2 (25.4) 28.7  7.3 (26.7) 0.21
Heart weight, g 351.5  75.8 (365.5) 359.6  67.1 (351) 0.67
RV chamber diameter 30.3  6.2 (30) 27.9  6.5 (25) 0.17
Anterior RV thickness, mm 2.5  1.1 (2) 2.6  1.0 (2) 0.71
Lateral RV thickness, mm 2.7  1.2 (2.5) 2.7  0.9 (3) 0.83
Posterior RV thickness, mm 3.5  0.9 (3.5) 3.3  0.7 (3) 0.31
RVOT epicardial fat, mm 0.7  1.5 (0) 1.0  1.2 (1) 0.21
RVOT muscle, mm 3.3  1.0 (3) 3.3  0.9 (3) 0.95
LV chamber diameter, mm 33.2  7.2 (35) 31.8  6.1 (31) 0.43
IVS diameter, mm 12.9  2.0 (13.5) 13.9  4.0 (13) 0.45
Anterior LV wall thickness, mm 11.8  2.3 (12) 11.9  2.1 (12) 0.85
Lateral LV wall thickness, mm 12.5  2.2 (12.5) 12.3  2.3 (12) 0.80
Posterior LV wall thickness, mm 11.9  1.8 (12) 11.7  1.8 (11.5) 0.58
Values are mean  SD (median) or n (%).
BrS ¼ Brugada syndrome; IVS ¼ interventricular septum; LV ¼ left ventricular; RV ¼ right ventricular;
RVOT ¼ right ventricular outflow tract.
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1516are therefore required for subsequent confirmatory
phases of the research. Statistical analyses were un-
dertaken using Stata IC/15 (StataCorp). One author
(I.C.S.) supervised the data analyses, which were
implemented by the first author (C.M.).
RESULTS
BRUGADA SCD POPULATION. The majority of the
BrS SCD cohort were men (21 of 28; 75%) and white
(26 of 28; 93%) with a median age at death of 25
years (IQR: 23-38.5 years). Death occurred in sleep in
16 of 28 (57%) cases and at rest in 8 of 28 (29%)
cases. Three deaths (11%) occurred either during
physical exertion or immediately after exertion.
Prior syncope was documented in 1 (1 of 28; 4%)
decedent. Of 6 antemortem BrS cases (6 of 28; 21%),
5 of 6 (83%) had shown a spontaneous type 1 Bru-
gada ECG, 1 later testing positive for a pathogenic
SCN5A mutation. None of the antemortem BrS group
demonstrated features of structural heart disease on
echocardiography, and 1 decedent underwent CMR
with negative late gadolinium assessment. Among
familial BrS cases (18 of 28; 64%), the mean number
of clinically evaluated first-degree relatives was 3.2
 1.0. Most cases (14 of 18; 78%) were diagnosed
based on the presence of a positive ajmaline provo-
cation challenge in 1 first-degree relative, none of
whom showed a spontaneous type 1 ECG. The me-
dian Shanghai score among antemortem BrS caseswas higher than in familial BrS cases (median 6.5
[IQR: 6.5-7] vs 3 [IQR: 2-3], respectively
[p ¼ 0.0002]). In SADS cases without familial eval-
uation or antemortem data, 4 tested positive for
pathogenic or likely pathogenic variants in SCN5A
(presumed to cause loss of function). Deaths in this
group similarly occurred at rest or during sleep.
None of the 14 BrS cases subjected to postmortem
genetic testing demonstrated likely pathogenic or
pathogenic variants in non-SCN5A arrhythmia and
cardiomyopathy-related genes. Demographics as
well as clinical and genetic characteristics of the BrS
SCD group are presented in Table 1.
CONTROL GROUP. Most sudden deaths in the
noncardiac death control group were caused by
opioid toxicity (22 of 29; 76%) or noncardiac trauma (3
of 29; 10%). The majority of control decedents were
men (25 of 29; 86%). The mean age at death was 32.1 
9.9 (range 18-54) and mean body mass index 28.7 
7.3 kg/m2. None of the control group had reported
antemortem cardiac symptoms or family history of
inherited cardiac disease or premature SCD.
MACROSCOPIC AND HISTOLOGICAL CARDIAC
APPEARANCES. Descriptive data and pathological
comparisons between case and control subjects are
presented in Table 2. There were no significant dif-
ferences with respect to age at death (P ¼ 0.56), sex
(P ¼ 0.28), or body mass index (P ¼ 0.21). Macroscopic
cardiac appearances, including height weight and
cardiac chamber dimensions, were similar in both
case and control subjects. Histological appearances of
cardiac tissue from each of the 6 sampled regions
demonstrated no evidence of inflammatory in-
filtrates, fibrofatty infiltration, or overt myocardial
fibrosis in either group.
MORPHOMETRIC QUANTIFICATION OF COLLAGEN
AND FAT. The mean sampled tissue areas for the
RVOT, RV, IVS, anterior LV, and posterior LV were
132.5  55.7 mm2, 247.6  75.1 mm2, 223.5  76.2 mm2,
239.5  61.2 mm2, and 245.2  56.1 mm2, respectively.
Table 3 outlines predicted values for the proportion of
collagen, fat, and myocytes (total, epicardial, and
endocardial) in the RVOT, RV, IVS, anterior LV and
posterior LV, stratified by Brugada and control group.
As shown in the Central Illustration and Table 3, the
highest proportion of collagen was observed in the
RVOT epicardium of the BrS group (geometric mean
23.7%; 95% CI: 20.8%-26.9%). Individual-level raw
data for collagen proportion are outlined in
Supplemental Table 2.
Cardiac tissue from BrS decedents demonstrated a
higher proportion of collagen when compared
with control subjects (ratio 1.45; 95% CI: 1.22-1.71;
P < 0.001). Between groups, there were no significant
TABLE 3 Predicted Values of Cardiac Tissue Composition Within the RVOT, RV, Septum, and Anterior and Posterior LV
RVOT RV Septum Anterior LV Posterior LV
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Brugada (n ¼ 28)
Collagen % of tissue area
Total 21.6 18.8-24.8 21.0 18.3-24.0 12.9 11.4-14.6 12.7 11.0-14.5 14.5 12.6-16.7
Epicardial 23.7 20.8-26.9 23.0 20.3-26.1 12.9 11.3-14.6 12.9 11.3-14.7
Endocardial 19.5 17.0-22.4 18.1 15.8-20.8 12.3 10.7-14.1 15.7 13.7-18.0
Fat % of tissue area
Total 7.8 5.7-10.6 12.7 9.4-17.2 1.8 1.4-2.4 7.1 5.2-9.6 3.2 2.4-4.4
Epicardial 11.6 8.1-16.5 21.5 15.2-30.5 11.1 7.8-15.7 4.5 3.2-6.5
Endocardial 3.5 2.7-4.5 4.7 3.6-6.0 2.8 2.1-3.6 2.3 1.8-2.9
Myocytes % of tissue area
Total 62.4 58.6-66.4 60.2 56.5-64.0 82.7 78.4-87.2 76.1 71.5-81.0 80.1 75.3-85.3
Epicardial 50.9 45.0-57.7 45.7 40.5-51.6 67.0 59.2-75.8 79.4 70.2-89.9
Endocardial 73.3 69.9-76.9 73.1 69.7-76.6 83.4 79.5-87.4 79.8 76.1-83.7
Control subjects (n ¼ 29)
Collagen % of tissue area
Total 14.6 12.4-17.1 15.9 13.5-16.7 8.6 7.4-9.9 9.1 7.7-10.6 9.9 8.4-10.6
Epicardial 15.4 12.8-18.5 16.3 13.5-19.8 9.4 7.8-11.3 8.8 7.3-10.6
Endocardial 13.3 11.3-15.6 14.0 11.8-16.5 8.7 7.4-10.2 10.4 8.9-12.2
Fat % of tissue area
Total 10.9 8.0-14.6 14.2 10.5-19.2 1.5 1.2-1.9 7.4 5.5-9.9 3.0 2.2-4.0
Epicardial 16.8 11.7-24.1 24.6 16.8-36.0 12.1 8.4-17.4 4.3 3.0-6.1
Endocardial 4.3 3.5-5.3 4.6 3.7-5.8 2.1 1.7-2.6 2.0 1.7-2.5
Myocytes % of tissue area
Total 67.9 64.5-71.5 64.0 60.7-67.4 88.6 84.9-92.4 78.3 74.4-82.4 84.1 79.9-88.6
Epicardial 55.4 49.2-62.3 48.6 42.9-55.0 67.7 60.1-76.2 81.4 72.4-91.5
Endocardial 79.8 77.3-82.3 79.3 76.7-82.0 87.4 84.6-90.2 82.2 83.5-88.9
Values are geometric means and corresponding 95% CIs of the predictions.
Abbreviations as in Table 2.
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1517interactions with respect to collagen proportion and
sampling location (RVOT, RV, IVS, anterior LV, pos-
terior LV) or collagen proportion and tissue layer
(epicardium/endocardium). Maximal increases in
collagen proportion were observed in the antemortem
BrS cohort (n ¼ 6) when compared with control sub-
jects (ratio 1.66; 95% CI: 1.25-2.20; P ¼ 0.001). The
familial BrS cohort (n ¼ 18) also demonstrated
significantly higher collagen proportions (ratio 1.42;
95% CI: 1.17-1.71; P < 0.001). However, there was
insufficient evidence to support differences in
collagen proportion in the pathogenic/likely patho-
genic SCN5A SADS group (n ¼ 4), when compared
with control subjects (ratio 1.29; 95% CI: 0.92-1.81;
P ¼ 0.14). Similarly, there was insufficient evidence to
support differences in collagen proportion in all cases
harboring a pathogenic/likely pathogenic SCN5A
variant (n ¼ 5), when compared with control subjects
(ratio 1.23; 95% CI: 0.75-1.43; P ¼ 0.27) or genotype
negative antemortem/familial BrS cases (n ¼ 13) (ratio
0.87; 95% CI: 0.64-1.18; P ¼ 0.37). In multivariable
analysis, there were no significant differences incollagen proportion according to sex (P ¼ 0.20), age at
death (P ¼ 0.91), or body mass index (P ¼ 0.92).
Overall, the proportion of fat was higher in female
than in male hearts (ratio 1.69; 95% CI: 1.21-2.36;
P ¼ 0.002) and in older compared with younger in-
dividuals (ratio per 5-year age increment: 1.08;
95% CI: 1.03-1.15; P ¼ 0.004). Maximal differences in
fat proportion (women vs men) were in the RVOT
(ratio 2.80; 95 CI: 1.65-4.70; P < 0.001) and RV (2.02;
95% CI: 1.22-3.40; P ¼ 0.006). There was insufficient
evidence to support differences in fat proportion ac-
cording to body mass index (P ¼ 0.23). After adjust-
ment for sex and age at death, both BrS and control
groups showed similar fat proportions, with no sig-
nificant differences with respect to sampling location
or myocardial layer (P ¼ 0.97).
DISCUSSION
In this study, we demonstrate that BrS is associated
with increased collagen content throughout RV and
LV myocardium, irrespective of sampling location or
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Collagen (top) and fat (bottom) proportions were determined from 6 sampled regions of ventricular myocardium. The highest proportions of collagen were observed
within the epicardial RVOT (23.7%; 95% CI: 20.8%-26.9%) and RV (23.0%; 95% CI: 20.3%-26.1%) of the BrS group. Cardiac tissue from BrS decedents demonstrated
a higher proportion of collagen when compared with noncardiac death control subjects (ratio 1.45; 95% CI: 1.22-1.71; P < 0.001), irrespective of sampling location or
myocardial layer. After adjustment for sex and age at death, both BrS and control groups showed similar fat proportions (P ¼ 0.97). BrS ¼ Brugada syndrome;
ENDO ¼ endocardial; EPI ¼ epicardial; IVS ¼ interventricular septum; LV ¼ left ventricle; LVAW ¼ left ventricular anterolateral wall; LVPW ¼ left ventricular
posterior wall; RV ¼ right ventricle; RVOT ¼ right ventricular outflow tract.
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1518myocardial layer. These findings were observed in the
absence of overt histological abnormality. To our
knowledge, this is the largest study evaluating car-
diac tissue from BrS decedents, incorporating blinded
automated quantification of myocardial tissue com-
ponents in a reproducible manner. Moreover, we go
beyond previous reports in systematically assessing
microstructural abnormalities in tissue architecture
within the LV myocardium. Conceivably, we proposethat proportional increases in epicardial collagen
within the thin-walled RVOT may contribute toward a
pathological tissue substrate and discontinuity of
conduction in BrS. In the setting of a disturbance in
transmural ion channel distribution and reduced so-
dium current, this would give rise to susceptibility to
re-entry and arrhythmogenesis.
PATHOLOGICAL FINDINGS. Overall, we identified a
45% increase in collagen proportions in the BrS group
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1519compared with control subjects, with the highest
proportion of collagen (24%) found within RVOT
epicardium. These data are consistent with previous
studies reporting the presence of interstitial fibrosis,
fractionated electrograms, and low-voltage regions
within RVOT epicardium, and may be in keeping with
the association of late potentials on signal-averaged
electrocardiography with elevated arrhythmic risk
(9,20,21). Taken together, these data ultimately sup-
port the depolarization hypothesis underlying con-
duction delay in BrS. Previously, Nademanee et al (10)
evaluated cardiac tissue from a group of 6 postmor-
tem SADS cases with a familial diagnosis of BrS,
reporting maximal increases (32%) in collagen pro-
portion in RVOT epicardium with respect to 6 age-
and sex-matched control subjects (10). We confirmed
an increasing gradient of RV endocardial to epicardial
collagen proportion, but did not observe significant
intergroup differences between sampling locations.
Therefore, in BrS, we hypothesize that normal RV
structural heterogeneities are responsible for
increased vulnerability to conduction slowing in the
presence of diminished sodium current and increased
fibrotic burden (22).
Others have also demonstrated the presence of
pathological histological substrate in BrS. In 2018,
Pieroni et al (23) reported interstitial and replacement
fibrosis in RVOT samples from 15 of 20 (75%) BrS pa-
tients undergoing RV biopsy. Interestingly, 80% of
these patients also showed evidence of myocardial
inflammation with lymphomononuclear infiltrates
comprised of activated T-lymphocytes. Although we
did not find overt features of inflammatory infiltrates
in postmortem tissue samples from either BrS or
control subjects, it is important to note that biopsies
in the study performed by Pieroni et al (23) were
performed under guidance from 3-dimensional elec-
troanatomic mapping and included immunohisto-
chemical analysis. The difference in sampling
technique and use of autopsy samples in our SCD
cohort cannot exclude temporal differences in dis-
ease pathogenesis or localized regions of myocardial
inflammation elsewhere in BrS myocardium. Howev-
er, our observations were broadly in line with a
pathological report by Zumhagen et al (24), which did
not describe inflammatory changes in myocardial bi-
opsy samples from 21 patients with BrS.
In the present study, we showed that there were no
significant differences in myocardial fat proportion
between BrS case and control subjects. A similar
conclusion was reached by Nademanee et al (10),
which is in contrast to earlier reports suggesting that
myocardial fatty infiltration in ACM may overlap his-
tologically with BrS (25,26). However, our data didyield age- and sex-specific differences in fat propor-
tion, with increased fat content associated with older
age and female sex demonstrating a 2-fold increase in
RV fat proportion when compared with men. This is
consistent with other pathological studies demon-
strating similar increases in cardiac fatty tissue depo-
sition, particularly among elderly women (27,28).
CLINICAL CORRELATIONS. Maximal differences in
collagen proportion were observed in the antemortem
BrS subgroup (n ¼ 6), which showed a 66% increase
when compared with control subjects. All antemortem
BrS decedents had achieved a probable or definite
diagnosis of BrS by the Shanghai criteria (score >3.5),
most having demonstrated a spontaneous type 1 ECG
during life, and one having tested positive for a path-
ogenic SCN5A mutation. Although the increased
collagen proportions in this groupmay associate with a
higher diagnostic certainty for BrS, there were no sig-
nificant differences in collagen proportion between
antemortem and familial BrS groups. However, our
data did not yield any significant differences in
collagen proportion between SADS decedents with
pathogenic or likely pathogenic SCN5A variants (n¼ 4)
and control subjects. This small group consisted of 3
missense mutations and 1 in-frame deletion, all
deemed pathogenic or likely pathogenic as per ACMG
criteria, and 2 of the variants had previously been re-
ported in probands with both BrS and LQTS type 3.
From this standpoint, the small sample size, lack of an
antemortem or familial discernible phenotype, and
pleotropic effects of SCN5A variantsmay partly explain
the lack of a statistically significant finding of greater
fibrosis in this subgroup.
UNDERLYING MECHANISMS AND LV INVOLVEMENT.
Despite ongoing debate about whether the repolari-
zation or depolarization hypothesis predominates in
BrS, there is growing consensus that the syndrome is
associated with mild structural abnormalities and a
reduced RVOT conduction reserve has been postu-
lated (22,29). Importantly, our data support that these
are independent of SCN5A genotype. We speculate
that an elevated fibrotic substrate burden in BrS may
affect heightened arrhythmogenesis through current-
to-load mismatch and excitation failure (30).
Furthermore, our data cast new light on the patho-
logical substrate underlying BrS, specifically finding a
consistent increase in collagen proportion throughout
ventricular myocardium, not just the RVOT. Indeed,
widespread proportionate increases in collagen
deposition suggests disease involvement throughout
both ventricles and may lend support to activation of
molecular pathways implicated in myocardial
fibrosis. Here, transcriptomic studies utilizing RNA
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: BrS is
associated with higher proportionate collagen content
throughout both LV and RV myocardium.
TRANSLATIONAL OUTLOOK: Future studies
should incorporate mRNA sequencing of myocardial
tissue specimens for transcriptome-wide analysis of
molecular pathways involved in collagen synthesis in
patients with BrS.
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assessment of global and/or regional differences in
molecular pathways implicated in collagen synthesis
in addition to the impact of rare SCN5A variants on
collagen expression.
Others have shown the presence of LV fibrosis in
BrS, both in vivo in a few cases using CMR and during
histological examination (10,11). Experimental
models also provide a mechanistic basis for this as-
sociation, albeit in hearts from a haploinsufficient
SCN5Aþ/ mouse model. For example, Jeevaratnam
et al (31) reported fibrotic changes within both right
and left ventricles, where epicardial activation anal-
ysis also demonstrated increased late conducting
components. Although CMR late gadolinium
enhancement imaging is an established technique to
assess replacement patterns of myocardial fibrosis, its
sensitivity is limited for the detection of diffuse
interstitial fibrosis (32). The findings from this study
warrant further investigation of BrS patients in vivo
using contemporary CMR techniques such as T1
mapping and extracellular volume assessment, as
described elsewhere (33).
STUDY LIMITATIONS. First, although a case-control
study design is recommended for rare outcomes,
there are some caveats that invite caution. Our study
was retrospective in nature and BrS is of low preva-
lence in the general population. Therefore, we were
limited by recruitment of SCD cases over a prolonged
period. Second, for SADS cases with a familial diag-
nosis of BrS, recruitment relied upon review of in-
vestigations performed at our hospital. It is possible
that additional SADS cases from the same overall
cohort may have been eligible for inclusion if clinical
data were available from family screening conducted
at other centers. Moreover, although the diagnosis of
familial BrS was achieved by accepted international
criteria (2), we cannot exclude the potential for
misclassification bias among the familial BrS group in
absence of an antemortem diagnosis. However, we
consider this unlikely given the inherited nature of
BrS, lack of alternative phenotype within the family,
and autopsy-negative sudden death in the proband.
Third, this study relied upon SCD referral to an expert
national cardiac pathology center. This may intro-
duce ascertainment bias, because the incidence of
SCD in BrS is low and such cases may represent a
more severe phenotype where myocardial fibrosis is
more prevalent. Finally, postmortem genetic testing
was limited by the number of retained genomic tissue
samples—a higher genetic yield would improve our
ability to investigate potential associations between
genotype and fibrotic burden.CONCLUSIONS
In this study, we systematically demonstrate that BrS
is associated with increased collagen content
throughout both ventricles, with maximal collagen
proportions observed within BrS RVOT epicardium.
These findings were not apparent during macroscopic
inspection of the heart or conventional histological
examination. Our study emphasizes the spectrum of
normal variation of collagen and fat content within
both ventricles, in contrast to a pathological increase in
collagen content found in BrS. In addition, we high-
light the potential utility of automated digital pathol-
ogy software to complement expertise provided by the
pathologist. Further research is required to elucidate
the mechanistic basis of fibrosis in BrS and understand
its cumulative effect on arrhythmic risk.
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